| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
RCE1 Blocking Peptide for STJ502759 is synthetically produced from the 300-350 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
RCE1 |
| Gene ID: |
9986 |
| Uniprot ID: |
FACE2_HUMAN |
| Immunogen Region: |
300-350 |
| Specificity: |
This blocking peptide is recommended for use in combination with RCE1 antibody, STJ502759 |
| Immunogen: |
Synthetic peptide taken within amino acid sequence 300-350 on human RCE1 protein. |
| Tissue Specificity | Ubiquitous. |
| Post Translational Modifications | Ubiquitinated. Undergoes 'Lys-48'- and 'Lys-63'-linked ubiquitination. 'Lys-48' ubiquitination induces its degradation. Deubiquitinated by USP17L2/USP17 that cleaves 'Lys-63'-linked ubiquitin chains. |
| Function | Proteolytically removes the C-terminal three residues of farnesylated and geranylated proteins. Seems to be able to process K-Ras, N-Ras, H-Ras, RAP1B and G-gamma-1. |
| Peptide Name | Caax Prenyl Protease 2Farnesylated Proteins-Converting Enzyme 2Face-2Prenyl Protein-Specific Endoprotease 2Rce1 HomologHrce1 |
| Database Links | Reactome: R-HSA-5689880Reactome: R-HSA-9648002 |
| Cellular Localisation | Endoplasmic Reticulum MembraneMulti-Pass Membrane Protein |
| Alternative Peptide Names | Caax Prenyl Protease 2 proteinFarnesylated Proteins-Converting Enzyme 2 proteinFace-2 proteinPrenyl Protein-Specific Endoprotease 2 proteinRce1 Homolog proteinHrce1 proteinRCE1 proteinFACE2 proteinRCE1A proteinRCE1B protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
